ALK and non-small cell lung carcinoma: Due to the recent discoveries of targetable genetic alterations in the treatment of NSCLC, patients have been stratified according to genetic variations in the primary tumor, including epidermal growth factor receptor (EGFR), KRAS, and anaplastic lymphoma kinase (ALK) (35).